To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Outcomes and Long-term Su… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Outcomes and Long-term Survival After Pulmonary Retransplantation: A Single-Center Experience

Journal article
Authors Andreas Wallinder
C. Danielsson
J. Magnusson
G. C. Riise
Göran Dellgren
Published in Annals of Thoracic Surgery
Volume 108
Issue 4
Pages 1037-1044
ISSN 0003-4975
Publication year 2019
Published at Institute of Medicine, Department of Molecular and Clinical Medicine
Pages 1037-1044
Language en
Keywords lung retransplantation, united-states, transplantation, registry, era, Cardiovascular System & Cardiology, Respiratory System, Surgery
Subject categories Molecular medicine (genetics and pathology)


Background. The median survival after lung retransplantation (ReLTx) reported to the International Society of Heart and Lung Transplantation is restricted to 2.5 years. We report the results after ReLTx from our center. Methods. A retrospective data collection was performed for the 635 patients who underwent lung transplantation between 1991 and 2017 at our center. Recipient variables were compared between patients undergoing only primary lung transplantation (PLTx) and those undergoing PLTx and later ReLTx. Time to death was compared using the Kaplan-Meier method. The risk of ReLTx was analyzed in Cox regression models. Any interaction between type of transplantation, single/double, and PLTx/ReLTx was investigated. Results. ReLTx was performed in 49 patients. Survival after ReLTx at 30 days and 1, 2, and 5 years was 90%, 76%, 71%, and 55%, respectively, and the corresponding survival after PLTx was 94%, 82%, 76%, and 61%, respectively. A hazard ratio of 1.73 for ReLTx was shown (95% confidence interval [CI], 1.14 to 2.63; P = .011). After adjustments for sex, age, diabetes, renal function, preoperative ventilator, and extracorporeal membrane oxygenation, the hazard ratio was 1.43 (95% CI, 0.90 to 2.26; P = .13). ReLTx was performed in 8 patients (16%) within the first year after PLTx. The 1-year survival for this group was 50% compared with 81% (P = .18) for patients who underwent ReLTx later than 1 year after the PLTx. One-year survival after double ReLTx was 60% (95% CI, 25% to 83%) compared with 79% (95% CI, 63% to 89%) for single ReLTx. Conclusions. ReLTx is a reasonable option for a selected group of patients. Ideally, a number of well-established risk factors are avoided and the ReLTx is performed more than 1 year after the PLTx. (C) 2019 by The Society of Thoracic Surgeons

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?